AUTHORS
Tracy George, MD, Ivan Alvarez-Twose, MD, PhD2, Vito Sabato, MD, PhD3, Jens Panse, MD4, Deepti H. Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed5, Sonia Cerquozzi, MD, FRCPC6, Candido E Rivera, MD7, Paul van Daele, MD, PhD8, Ingunn Dybedal, MD, PhD9, Jay Patel, MD10, Anton Rets, MD, PhD11, Karen Moser, MD12, Madhu P. Menon, MD, PhD, FACP, FASCP13, Lindsay Rein, MD14, Daniel J DeAngelo, MD, PhD15, Amanda Pilla, BS16, Jenna Zhang, PhD17, Priya Singh, PharmD18, Raheela Soomro, MD19, Rachael Easton, MD20, Nathan Boggs, MD, PhD21
AFFILIATIONS
1 University of Utah, ARUP Laboratories, Salt Lake City, Utah, United States
2 Instituto de Estudios de Mastocitosis de Castilla-La Mancha, Hospital Virgen del Valle, Toledo, Spain
3 Antwerp University Hospital (UZA), Edegem, Belgium
4 Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen, Germany, University Hospital RWTH Aachen, Aachen, Germany
5 Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
6 University of Calgary, Calgary, Canada
7 Mayo Clinic, Jacksonville, Florida, United States
8 Erasmus Medical Center, Rotterdam, Netherlands
9 Oslo University Hospital, Oslo, Norway
10 University of Utah, ARUP Laboratories, Salt Lake City, Utah, United States
11 University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States
12 Huntsman Cancer Institute, University of Utah, ARUP Laboratories, Salt Lake City, Utah, United States
13 Huntsman Cancer Institute, University of Utah, ARUP Laboratories, Salt Lake City, Utah, United States
14 Duke Cancer Institute, Durham, North Carolina, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
17 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
18 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
19 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
20 Cogent Biosciences, Inc., Waltham, Massachusetts, United States
21 Uniformed Services University & Walter Reed National Military Medical Center, Bethesda, Maryland, United States
ABSTRACT
Introduction
The systemic mastocytosis (SM) subtypes, bone marrow mastocytosis (BMM), indolent SM (ISM), and smoldering SM (SSM) – collectively known as nonadvanced SM (NonAdvSM)– are characterized by neoplastic mast cell (MC) accumulation in extracutaneous tissues and are driven by the activating KIT D816V mutation in most patients. Clinical, pathologic, laboratory, and molecular parameters, including the degree of bone marrow MC accumulation, are used to measure the MC burden and determine SM subtype.
Bezuclastinib is an oral, potent, type 1 tyrosine kinase inhibitor with high selectivity for KIT p.D816V. Results from the randomized, placebo-controlled portion of the Summit study (NCT05186753) in patients with NonAdvSM demonstrated clinically meaningful symptom improvement and significant reductions in objective disease markers including bone marrow MC burden, serum tryptase, and KIT D816V variant allele frequency with bezuclastinib at 24 weeks. Further analyses of bone marrow demonstrated marked reduction of dense MC aggregates and normalization of atypical MC morphology and aberrant immunophenotype. In total, 55% of patients achieved complete resolution of SM diagnostic criteria with bezuclastinib treatment after 24 weeks of treatment.
The randomized portion of Summit was followed by an open-label extension period, during which all patients received bezuclastinib. Here, we describe the long-term effect of bezuclastinib treatment on bone marrow pathology in patients who received 72 weeks of bezuclastinib treatment.
Methods
The randomized portion of Summit evaluated the efficacy and safety of bezuclastinib in patients with NonAdvSM who had inadequate symptom control despite optimized anti-mediator therapy. The primary endpoint evaluated change in symptom severity utilizing a patient-reported outcome measure. Key secondary endpoints included changes in objective disease markers. Bone marrow biopsy was performed at baseline, at the end of the double blinded randomized period, and as an optional assessment during the open-label extension. Bone marrow evaluations included assessment of MC burden, MC aggregates, morphology, and immunophenotype. Immunohistochemical staining was performed on bone marrow specimens using standard methodology.
Results
A total of 21 patients had serial bone marrow assessments at baseline, week 24, and week 72. Median bone marrow MC burden of 10% at baseline decreased to 3% at week 24 and to 2% at week 72. Dense MC aggregates, the major criterion for SM diagnosis, were present in 15/21 (71%) patients at baseline; the number of patients with aggregates decreased to 4/21 (19%) at week 24 and further to 2/21 (10%) at week 72, indicating substantial resolution of pathologic MC clustering. In addition, the percent of patients with mostly spindle-shaped (aberrant morphology) vs predominantly round/oval (normal morphology) MCs was 91% vs 0% at baseline; this improved to 43% vs 57% at 24 weeks and further improved to 21% vs 79% at week 72, indicating progressive normalization of MC morphology.
All 21 patients had expression of the aberrance MC surface marker CD25 at baseline. Nineteen of 21 patients had a reduction in CD25 by week 24, with reduction ranging from 25% to 100%. Complete elimination of CD25 expression was achieved in 11/21 patients (52%) by week 24 and this increased to 18/21 (86%) by week 72. Thirteen of the 21 patients had expression of the aberrant MC surface marker CD30 at baseline; of these, 12 patients had a reduction by week 24, with reduction ranging from 83% to 100%. Complete elimination of CD30 expression was achieved in 11/13 patients (85%) by week 24 and 10/13 patients (77%) by week 72, indicating durable suppression of aberrant CD30 expression in the majority of patients. These results demonstrate progressive immunophenotypic normalization of MCs with bezuclastinib treatment in the majority of patients that continues beyond 24 weeks.
Conclusions
Treatment with bezuclastinib for 72 weeks results in durable and progressive normalization of MC morphology in most patients, elimination of MC aggregates, and normalization of the MC phenotype.
DISCLOSURES
Tracy George, MD: Incyte - Consultancy (Includes expert testimony); Blueprint Medicines Corporation, a wholly owned subsidiary of Sanofi - Consultancy (Includes expert testimony); Celgene - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony)